Article thumbnail

Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples

By Shinji Mizuarai, Takumitsu Machida, Tsutomu Kobayashi, Hideya Komatani, Hiraku Itadani and Hidehito Kotani
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). Abnormal expression of p16(INK4a), CCND1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
  2. (1995). BJ: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res
  3. (1995). Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol
  4. (2004). Cordon-Cardo C: Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature
  5. (2011). Correlation of clinicopathological features with immunohistochemical expression of cell cycle regulatory proteins p16 and retinoblastoma: distinct Mizuarai et al. Molecular Cancer
  6. (2003). Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res
  7. (2001). Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma. Pathobiology
  8. (2002). E: The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer
  9. (2002). ES: Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication.
  10. (2007). ES: The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
  11. (2002). ES: Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res
  12. (2004). Fesik S: siRNA-mediated gene silencing: a global genome view. Nucleic Acids Res
  13. (2002). Friedl A: Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett
  14. (2004). Inoue I: Expression of MCM10 and TopBP1 is regulated by cell proliferation and UV irradiation via the E2F transcription factor. Oncogene
  15. (2008). Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. Curr Mol Med
  16. (2002). Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function.
  17. (2009). Kotani H: Discovery of Gene Expression-Based Pharmacodynamic Biomarker for a p53 Context-Specific Anti-Tumor Drug Wee1 Inhibitor. Mol Cancer
  18. (2006). Leonardo A: RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol Cancer
  19. (1999). Löning T: P16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch
  20. (2003). Methylation and expression of gene p16INK4a and RB in gastric carcinomas. Beijing Da Xue Xue Bao
  21. (2007). MF: Retinoblastoma deficiency increases chemosensitivity in lung cancer. Cancer Res
  22. (2004). NH: The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol
  23. (2007). Niesters HG: Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.
  24. (2000). Pestell RG: CCND1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol
  25. (2002). RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene
  26. (2007). RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene. Oncogene
  27. (1995). Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA
  28. (1997). Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. Gynecol Oncol
  29. (2000). Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain. Oncogene
  30. (1999). Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev
  31. (2003). SJ: Abnormal expression of pRb, p16, and CCND1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol
  32. (1999). Strebhardt K: Expression of p16 and lack of pRB in primary small cell lung cancer.
  33. (2008). Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer
  34. (2002). The RB and p53 pathways in cancer. Cancer Cell
  35. (1998). The regulation of E2F by pRB-family proteins. Genes Dev
  36. (2006). Vocaturo A: Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol
  37. (1998). WF: Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res
  38. (1999). WH: p53, p16 and RB expression in adenosquamous and squamous cell carcinomas of the stomach. Pathol Res Pract
  39. (2005). Y: Expression of p16 gene and Rb protein in gastric carcinoma and their clinicopathological significance.
  40. (2001). Zacny VL: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene
  41. (2008). Zheleva D: The Basis of Cell Sensitivity to Aurora A/B Inhibitors.